A retrospective analysis of more than 264,000 pregnancies in southern Israel has found that non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, taken during the first trimester, do not raise the risk of major congenital malformations, and that paracetamol is safe throughout pregnancy. The study, drawing on two decades of data from the siPREG registry and published in PLOS Medicine and Human Reproduction Open, adjusted for maternal fever, inflammatory diseases and chronic illness. After these adjustments, the apparent association between painkiller use and birth defects disappeared, indicating that earlier raw signals were driven by the underlying conditions being treated rather than the medications themselves.

The findings arrive as a separate analysis of over three million supermarket transactions, combined with a review of 80 clinical trials involving 5,800 women, demonstrates that ibuprofen and other NSAIDs are significantly more effective than paracetamol for dysmenorrhoea, yet paracetamol remains the most purchased remedy. NSAIDs work by inhibiting cyclooxygenase enzymes and reducing prostaglandin production, directly targeting the cause of menstrual cramps, whereas paracetamol acts primarily on pain perception in the central nervous system and has little anti-inflammatory effect. Researchers in Beersheba note that the pregnancy data provide clarity for women and clinicians who have long faced conflicting advice, and they call for a shift toward evidence-based reassurance that treats the underlying condition rather than avoiding medication.

Viewed from London, the search for hormonal solutions has driven growing patient interest in supplements such as inositol, frequently discussed on social media for polycystic ovary syndrome and hormonal acne. Clinicians report that women increasingly arrive at consultations already taking the compound, though robust clinical trial data remain limited compared with established pharmaceuticals. Personal accounts from Germany and the Americas underscore the psychological toll of visible skin disorders and chronic illness: a German essay describes the emotional drain of persistent acne, while an American influencer details years of facial disfigurement from a suspected benign tumour, and a model publicly shares a Lyme disease flare-up that brought severe isolation and depression.

The Israeli researchers emphasise that the next step is for obstetrics and dermatology societies to incorporate these large-scale safety data into updated clinical guidelines. The menstrual pain research, meanwhile, highlights a persistent knowledge gap between evidence and consumer behaviour, likely sustained by marketing and perceptions of safety. As the burden of visible and chronic conditions continues to draw attention, the convergence of rigorous registry data and real-world purchasing patterns offers a clearer path for both prescribers and patients.